Status:
TERMINATED
Acupuncture for Joint Symptoms in Patients With Breast Cancer
Lead Sponsor:
The Hong Kong Polytechnic University
Collaborating Sponsors:
The Affiliated Hospital Of Southwest Medical University
Conditions:
Female Breast Cancer
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Joint symptoms including stiffness, local pain and aches are common adverse reactions among breast cancer (BC) patients undergoing hormone treatments, while effective interventions for managing such s...
Detailed Description
A three-group trial design is proposed, with an experimental group receiving true acupuncture at specific acupuncture points, a sham control group receiving sham acupuncture at non-acupuncture Acupoin...
Eligibility Criteria
Inclusion
- BC patients with a confirmed diagnosis of hormone receptor-positive BC at the stage of I, II or IIIa;
- Patients who have completed taxane-based chemotherapy and are currently undergoing hormone treatments for at least three months;
- Patients indicate ongoing joint symptoms, including joint pain and/or stiffness, at one or more sites of body;
- Patients started to experience the joint symptoms after the commencement of the hormone treatments;
- Patients indicate the intensity of their worst pain during the past seven days of greater than 4 points at a 0-10 NRS scale where 0 represents no pain and 10 indicates most severe pain;
- Patients have at least a primary school education and are able to communicate in Chinese Mandarin or Sichuanese; and
- Patients agree to participate in the trial and are willing to give written informed consent.
Exclusion
- Patients who had needle phobia and a low count of platelet of less than 50,000;
- Patients with conditions which are not appropriate for acupuncture including pregnancy, bleeding disorders, local or systematic inflammation, and other neuropathic and/or metabolic problems of the joints;
- Patients who had received joint surgery or had bone fracture during the past six months;
- Patients who had received any types of acupoint stimulation (e.g. body acupuncture or acupressure and auricular therapy) during the past six months; and
- Patients are currently treated with narcotic analgesia or steroids.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03836872
Start Date
March 1 2019
End Date
January 31 2022
Last Update
August 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xianliang Liu
Luzhou, China